Composition and administration of emu oil

Маслото от ему се добива от щраусоподобни нелетящи птици, характерни за територията на Австралия. Извлича се от голямо струпване на мазнини, намиращо се на гърба на птицата.Съставът на маслото от ему дава обяснение на изключителните му свойства. Състои се главно от ненаситени мастни киселини - олеинова, линоленова и алфа-линоленова. Съдържа и наситени мастни киселини - палмитинова, стеаринова, миристинова, арахидонова, гадоелинова. Богато е и на витамини А, Е и F.Доказано е, че маслото от ему е мощен трансдермален агент, който може да проникне дълбоко в кожата и ефектът му не е само върху повърхностните слоеве. Маслото е ефективно за широко приложение. То има противовъзпалително, антибактериално и антиалергично действие, повишава клетъчното възпроизвеждане, прониква бързо и дълбоко в кожата и не запушва порите.Може да се прилага за:• успокояване и намаляване на възпалението, свързано с акне, дерматит, екзема, псориазис;• намаляване на възпалението и подуването на мускули и стави при артрит;• заличаване на белези от скорошни рани и превенция срещу стрии; • изгаряния;• овлажняване на суха и напукана кожа, редуцира бръчки и петна;• активира космените фоликули на скалпа и стимулира растежа на нова коса;• за масаж при хронични травми.Доказано е отсъствието на странични ефекти при прилагането на масло от ему.Поради трансдермалните му способности то може да увеличи ползите от други продукти, използвани едновременно. Съчетава се добре с гел от алое, масло от нар, масло от семена на шипка, масло от карите, рициново масло, водорасли и морски колаген, кокосово масло, витамини А, Е, D, глюкозамин. То е добър емулгатор и се смесва успешно с други масла и вода, без да оставя мазен филм върху кожата или скалпа.Emu oil is obtained from birds belonging to the ostrich family during processing. They typically live in Australia. The oil is extracted from the oil mass located on the back of the bird.Emu oil has extraordinary properties. It consists mainly of polyunsaturated fatty acids , oleic acid and omega 9, and saturated fatty acids - palmitic acid, stearic acid, miristic acid, arachidonic acid, gadoleic acid. It is also rich in vitamins A, E and F.It has been proven that emu oil is a powerful deep tissue agent and its positive qualities go far beyond benefiting surface layers of the skin. The oil has a broad spectrum of uses because of its anti- inflammatory, anti-bacterial and anti-allergic properties. Emu oil regenerates cellular activity and does not block pores.It can be used for:• Reducing inflammation connected to acne, dermatitis, eczema and psoriasis;• Reducing inflammation and swelling of muscles and joints , relieving arthritis pain;• Healing of scars and burns;• Protecting against stretch marks;• Moisturizing dry and cracked skin;• Reducing the appearance of stretch marks;• Activating hair follicles on scalp to stimulate hair growth;• Massage in chronic muscle pain and long-term injuries.Emu oil combines well with other products due to its deep tissue penetration qualities. It works in balance with aloe, pomegranate oil, rose hip oil, shea butter, castor oil, seaweed and marine collagen, coconut oil, vitamins A, E, D and glucosamine. It blends successfully with other oils and water without leaving greasy residue on skin and scalp

Experimental model for visualization of tissue redox status in dopaminergic area of the brain using MRI

後日入

60 Years “Assistant – Pharmacist” In Varna

A brief historical overview of the development of the pharmacy work, the profession “Assistant pharmacist” and the pharmaceutical organizations in Bulgaria on the occasion of the 60th anniversary of the profession in Varna.Before the Liberation of Bulgaria, persons with insufficient pharmaceutical training performed the medical care of the population. After the Liberation, the “Temporary rules for the organization of pharmacies in Bulgaria” were created. According to the rules, the managers of the pharmacies were required to be master pharmacists, but until 1895 only 18 people have a legal degree in pharmacy. On August 11, 1883, a “Regulation for the admission of pharmacy students and assistants in pharmacies” has been established, which marks the beginning of the training of pharmacy assistants, whose training takes place in pharmacies

Docosahexaenoic Acid Sensitizes Leukemia Lymphocytes to Barasertib and Everolimus by ROS-dependent Mechanism Without Affecting the Level of ROS and Viability of Normal Lymphocytes

The aim of the present study was: (i) to investigate the possibility of sensitizing leukemia lymphocytes to anticancer drugs using docosahexaenoic acid (DHA); (ii) to find combinations with synergistic cytotoxic effect on leukemia lymphocytes, without or with only very low cytotoxicity towards normal lymphocytes; (iii) and to clarify the role of reactive oxygen species (ROS) in the induction of apoptosis and cytotoxicity by such combinations. The study covered 15 anticancer drugs, conventional and new-generation. Well-expressed synergistic cytotoxic effects were observed after treatment of leukemia lymphocytes (Jurkat) with DHA in combination with: barasertib, lonafarnib, everolimus, and palbociclib. We selected two synergistic combinations, DHA with everolimus or barasertib, and investigated their effects on viability of normal lymphocytes, as well as on the production of ROS and induction of apoptosis in both cell lines (leukemia and normal). At the selected concentrations, DHA, everolimus and barasertib (applied separately) were cytotoxic towards leukemia lymphocytes, but not normal lymphocytes. In leukemia cells, the cytotoxicity of combinations was accompanied by strong induction of apoptosis and production of ROS. In normal lymphocytes, drugs alone and in combination with DHA did not affect the level of ROS and did not induce apoptosis. To our knowledge, the present study is the first to report synergistic ROS-dependent cytotoxicity between DHA and new-generation anticancer drugs, such as everolimus and barasertib, that is cancer cell-specific (particularly for acute lymphoblastic leukemia cells Jurkat). These combinations are harmless to normal lymphocytes and do not induce abnormal production of ROS in these cells. The data suggest that DHA could be used as a supplementary component in anticancer chemotherapy, allowing therapeutic doses of everolimus and barasertib to be reduced, minimizing their side-effects

Systematic study on the cytotoxic and/or cytostatic effects of over twenty anticancer drugs: The crucial importance of the analytical approach and data processing

The aim of this study was to clarify the real cytotoxic effect of anticancer substances, by using a highly standardized analytical approach and precise data processing.Over twenty anticancer drugs (new generations) were tested on cultured cell lines. Cell viability and proliferation were analysed and different data processing was applied. Based on the conventional approach for calculation of cell viability as a percentage from the respective control, all drugs could be characterized as cytotoxic. Based on the effect of the drugs on the number of viable cells in each treated sample (compared to the initial value), they could be divided in threegroups: (i) cytotoxic drugs; (ii) strongly cytostatic drugs, but not cytotoxic; (iii) drugs without effect on cell viability and with comparatively weak cytostatic effect. The study shows the crucial importance of the analytical approach and the data processing. It is obligatory to control the effect of the drug on the number of viable cancer cells during the treatment, comparing to the initial value. In most cases, the cancer cells stay alive in the presence of drug(depending on the selecting dose) and it is a matter of time these cells to start to proliferate again after termination of the treatment

In vitro analysis of redox status of normal and tumor cells using nitroxide radicals and EPR spectroscopy

In present study we describe in vitro imaging analysis of cellular redox status in cancer and noncancer cells, using two redox-sensitive nitroxide derivatives (methoxy-TEMPO and mito-TEMPO) and electron paramagnetic resonance (EPR) spectroscopy. The nitroxide radical (which is characterized by EPR contrast) participates in electron-transfer reactions with variety of intracellular oxidative and reducing equivalents. The rate constants of these reactions determine the EPR signal dynamics in cell suspension. In non-cancer cells, EPR signal intensity of nitroxides decreased significantly during incubation. In cancer cells, EPR signal intensity was almost constant within two hours incubation and did not decreased significantly. The data suggest that non-cancer cells are characterized by a higher reducing activity to the nitroxide radical, while cancer cells are characterized by a higher oxidative activity. The described methodology is appropriate sensing platform for differentiation of cancer from non-cancer cells based on their redox status

Redox-modulating and/or antioxidant properties of nitroxides – a potential reason for decreasing side-effects of cancer therapy

The existing therapeutic approaches – radiation therapy and conventional chemotherapy of cancer, suffer of serious side-effects as a result of increased generation of reactive oxygen and nitrogen species (ROS/RNS) in non-cancer cells and tissues. Currently, the development of oxidative stress in non-cancer tissues of cancer-bearing organism is a serious problem of cancer therapy. It is necessary to ask about a combination of substances expressing a therapeutic synergism as a result of differentiated effects on cancer and normal cells: substances with increased ROS/RNS-scavenging properties targeting normal cells and substances with increased ROS/RNS-generating properties targeting cancer cells. In this context, the redox-modulators are one of the most attractive candidates. The present review outlines the basic principle of this novel therapeutic strategy, focusing on nitroxide derivatives as one of the most promising redox-modulators with antioxidant ability

Electro-assisted drug delivery in cancer using size-controlled long-circulating polymer nanoparticles

後日入力24th International Conference of the Society of Bulgarian Scientists